By Maggie Fick and Stine Jacobsen LONDON/COPENHAGEN (Reuters) -Wegovy maker Novo Nordisk on Wednesday forecast sales would grow at a slower rate this year although the outlook was roughly in line with ...

The Danish pharmaceutical company’s blockbuster Wegovy weight-loss drug just missed sales expectations in the fourth quarter ...

Sales of Novo Nordisk’s obesity drug, Wegovy, rose by more than 50 per cent last year, helping the Danish drugmaker beat revenue expectations.

Danish pharmaceutical behemoth Novo Nordisk reported better-than-expected net profit in the fourth quarter, amid soaring ...

Toyota Motor sold 10.8 million vehicles globally in 2024, retaining its position as the world's biggest carmaker. The Japanese automakers had announced a plan to combine in December. Novo's Wegovy and ...

Wegovy maker Novo Nordisk on Wednesday forecast slower sales growth for 2025 than 2024, a blow that is likely to deepen ...

Eli Lilly is set to report fourth-quarter earnings early Thursday, with analysts expecting rising sales and profit in the first full quarter with the company's weight-loss drugs no longer in shortage.

Novo’s Wegovy and Ozempic are among the most closely watched new medications in recent history, but face serious competition ...

Investors are upset at a lack of clarity over the results of Wegovy successor CagriSema after trials published in December.

These launches are positioned for multi-blockbuster status, thanks to their promise of fulfilling unmet needs, impacting ...